NEW YORK (GenomeWeb) – DermTech announced today that it has raised $10 million of its Series C preferred equity offering.
"We are very pleased to have the investor support allowing us to reach $10 million in preferred stock sold out of our $15 million offering," DermTech CFO Steve Kemper said in a statement.
The company said it would use the proceeds of the offering to continue the expansion of its sales force and bring new skin cancer products to market in 2018.